[Prognostic value of neuron enolase levels in serum of patients with lung neoplasms].
The aim of this study was to assess a prognostic value of serum specific enolase (NSE) measurement in lung cancer patients. Total number of 105 patients entered the study, including 36 patients with small cell carcinoma and 69 patients with non small cell carcinoma (21-squamous cell carcinoma, 32-adenocarcinoma, 14-large cell carcinoma). Elevated NSE level was observed in 47 (44.8%) patients: in 75% of SCLC patients and 29% of NSCLC patients (p < 0.001). Median survival in NSCLC patients with elevated NSE levels was 27 weeks and in those with normal values-59 weeks. The probability of one year survival in both groups was 22% and 45% respectively (p = 0.27). Median survival in SCLC patients with elevated NSE test was 30 weeks and in those normal levels-61 weeks and the probability of one years survival in both groups was 26% and 62%, respectively (p = 0.34).
Jassem
E
E
Kliniki Chorób Płuc i Gruźlicy AM w Gdańsku.
Gan
J
J
Cynowska
B
B
D000230:Adenocarcinoma / Q000201:enzymology / Q000401:mortality; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D011379:Prognosis; D018709:Statistics, Nonparametric; D015996:Survival Rate
D010751:Phosphopyruvate Hydratase
Rokownicza wartość oznaczania stezenia swoistej enolazy neuronowej w surowicy chorych na raka płuca.